<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931654</url>
  </required_header>
  <id_info>
    <org_study_id>D9570C00001</org_study_id>
    <secondary_id>2021-000036-57</secondary_id>
    <secondary_id>152970</secondary_id>
    <nct_id>NCT04931654</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer</brief_title>
  <official_title>A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3&#xD;
      bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This first time in patients, open-label, multi-centre study will have AZD7789 administered&#xD;
      intravenously (IV) to participants with advanced solid tumors. This study will have 2 parts:&#xD;
      Part A which will have dose escalation cohorts and Part B which will have the dose expansion&#xD;
      cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a FTIH, multicenter, open-label, dose-escalation and dose-expansion study. The study includes 2 parts: Part A Dose Escalation and Part B Dose Expansion. Initially, participants with Stage IIIB to IV NSCLC will be enrolled in the study; additional tumor types may be explored and added in a future amendment to the CSP.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)</measure>
    <time_frame>From time of Informed Consent to 90 days post last dose of study intervention</time_frame>
    <description>Number of participants with AEs, SAEs, imAEs including AEs leading to discontinuation of study intervention and clinically significant alterations in vital signs, laboratory parameters and ECG results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol</measure>
    <time_frame>From the first patient until the end of the dose escalation period; approximately 18 months.</time_frame>
    <description>A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary anti-tumour activity of AZD7789</measure>
    <time_frame>From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.</time_frame>
    <description>Objective response rate as defined by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From first participant until last participant assessment; a duration of approximately 4 years. Disease assessments will be performed until progression or initiation of another anticancer therapy.</time_frame>
    <description>Objective response rate as defined by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>From first documented response to confirmed progressive disease or death; approximate duration of 4 years.</time_frame>
    <description>The percentage of participants according to RECIST v1.1 with a response or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From first documented response to confirmed progressive disease or death; approximate duration of 4 years.</time_frame>
    <description>The time from first response according to RECIST v1.1 until progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From first dose of study intervention to confirmed progressive disease or death; approximate duration of 4 years.</time_frame>
    <description>The time from first dose of study intervention until the date of objective disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From first dose of study intervention to death. Overall survival will be monitored for the duration of the study, which will last approximately 4 years.</time_frame>
    <description>The time from first dose of study intervention until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD7789: Maximum plasma concentration of the study drug (Cmax)</measure>
    <time_frame>From first dose of study intervention, at predefined intervals throughout the administration of study intervention; approximately 4 years.</time_frame>
    <description>Maximum observed plasma concentration of the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AZD7789</measure>
    <time_frame>From first dose of study intervention, at predefined intervals throughout the administration of study intervention. A duration of approximately 4 years.</time_frame>
    <description>The number and percentage of participants who develop detectable anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD7789: Area Under the concentration-time curve (AUC)</measure>
    <time_frame>From first dose of study intervention, at predefined intervals throughout the administration of study intervention; approximately 4 years.</time_frame>
    <description>Area under the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD7789: Clearance</measure>
    <time_frame>From first dose of study intervention, at predefined intervals throughout the administration of study intervention; approximately 4 years.</time_frame>
    <description>A pharmacokinetic measurement of the volume of plasma from which the study is completely removed per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD7789: Terminal elimination half-life (t 1/2)</measure>
    <time_frame>From first dose of study intervention, at predefined intervals throughout the administration of study intervention; approximately 4 years.</time_frame>
    <description>Terminal elimination half life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) acquired resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7789 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part B1: NSCLC IO acquired resistance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7789 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Part B2: NSCLC IO naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD7789 Monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD7789</intervention_name>
    <description>anti-PD-1 and anti-TIM-3 bispecific antibody</description>
    <arm_group_label>Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) acquired resistance</arm_group_label>
    <arm_group_label>Dose Expansion Part B1: NSCLC IO acquired resistance</arm_group_label>
    <arm_group_label>Dose Expansion Part B2: NSCLC IO naive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be â‰¥ 18 years of age&#xD;
&#xD;
          -  Histologically or cytologically documented Stage IIIB to IV non-small cell lung&#xD;
             carcinoma (NSCLC) not amenable to curative surgery or radiation&#xD;
&#xD;
          -  Must have at least one measurable lesion according to Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Provision of fresh tumor tissue sample and consent to undergo mandatory on-treatment&#xD;
             biopsy for participants enrolled in Part A Dose-escalation&#xD;
&#xD;
          -  Provision of archival tumor tissue sample or fresh tissue sample for Part B&#xD;
             Dose-expansion participants&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Non-pregnant women and willingness of female participants to avoid pregnancy or male&#xD;
             participants willing to avoid fathering children through highly effective methods of&#xD;
             contraception&#xD;
&#xD;
          -  Adequate organ and bone marrow function measured within 28 days prior to first dose&#xD;
&#xD;
        Part A Dose Escalation Additional Inclusion Criteria:&#xD;
&#xD;
          -  May have squamous or non-squamous NSCLC&#xD;
&#xD;
          -  Must have received at least one prior line of systemic therapy, of which only one&#xD;
             prior line of therapy contained approved anti-PD-1/PD-L1&#xD;
&#xD;
          -  Must have had immune-oncology (IO) acquired resistance&#xD;
&#xD;
          -  PD-L1 TPS â‰¥ 1% documented&#xD;
&#xD;
        Part B Dose Expansion Cohort B1 Additional Inclusion Criteria:&#xD;
&#xD;
          -  Must have non-squamous NSCLC&#xD;
&#xD;
          -  Must have received at least one but no more than 2 prior lines of systemic therapy, of&#xD;
             which only one prior line of therapy contained approved anti-PD-1/PD-L1&#xD;
&#xD;
          -  Must have had IO acquired resistance&#xD;
&#xD;
          -  PD- L1 TPS â‰¥ 1% documented&#xD;
&#xD;
        Part B Dose Expansion Cohort B2 Additional Inclusion Criteria:&#xD;
&#xD;
          -  Must have non-squamous NSCLC&#xD;
&#xD;
          -  Must not have received prior systemic therapy including IO therapy in the first-line&#xD;
             setting&#xD;
&#xD;
          -  PD-L1 TPS â‰¥ 50% documented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sensitizing epidermal growth factor receptor (EGFR) mutations or&#xD;
             anaplastic lymphoma kinase (ALK) fusions&#xD;
&#xD;
          -  Documented test result for any other known genomic alteration for which a targeted&#xD;
             first line therapy is approved per local standard of care (SoC)&#xD;
&#xD;
          -  Unresolved toxicities of â‰¥ Grade 2 from prior therapy&#xD;
&#xD;
          -  Any prior â‰¥ Grade 3 imAE while receiving immunotherapy or any unresolved imAE â‰¥ Grade&#xD;
             2&#xD;
&#xD;
          -  Must not have experienced a toxicity that led to permanent discontinuation of prior&#xD;
             immunotherapy&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastasis or leptomeningeal disease&#xD;
&#xD;
          -  Any venous or arterial thromboembolic event within 6 months prior to study drug dosing&#xD;
&#xD;
          -  History of organ transplant&#xD;
&#xD;
          -  Infectious disease exclusions: Active infection including TB, HIV, hepatitis A,&#xD;
             chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19&#xD;
             infection&#xD;
&#xD;
          -  History of arrhythmia which is symptomatic or requires treatment; symptomatic or&#xD;
             uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained&#xD;
             ventricular tachycardia&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, cardiomyopathy of any etiology, symptomatic congestive heart failure,&#xD;
             uncontrolled hypertension, uncontrolled diabetes mellitus, unstable angina pectoris,&#xD;
             history of myocardial infarction within the past 6 months, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, active non infectious skin&#xD;
             disease&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders, including&#xD;
             inflammatory bowel disease (eg, colitis or Crohn's disease), diverticulitis (with the&#xD;
             exception of diverticulosis), systemic lupus erythematosus, Sarcoidosis syndrome, or&#xD;
             Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc.. Some exceptions have been specified in the&#xD;
             protocol&#xD;
&#xD;
          -  Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation&#xD;
             pneumonitis requiring steroid treatment, or any evidence of clinically active ILD&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to the first dose of study intervention&#xD;
             or still recovering from prior surgery&#xD;
&#xD;
          -  Other invasive malignancy within 2 years prior to screening&#xD;
&#xD;
          -  Congenital long QT syndrome or history of QT prolongation associated with other&#xD;
             medications that cannot be changed or discontinued based on a cardiologist assessment&#xD;
&#xD;
          -  Previous treatment with anti-CTLA-4 or anti-TIM-3 therapy in any setting&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days prior to the first&#xD;
             dose of study intervention&#xD;
&#xD;
          -  Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal&#xD;
             therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer-related&#xD;
             conditions is acceptable.&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of study&#xD;
             intervention. Note: Participants should not receive live vaccine while receiving study&#xD;
             intervention and up to 30 days after the last dose of study intervention&#xD;
&#xD;
          -  Radiotherapy treatment to the lung within â‰¤ 4 weeks of the first dose of AZD7789.&#xD;
             Palliative bone radiotherapy is allowed if â‰¥ 2 weeks prior to the first dose of&#xD;
             AZD7789.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumor</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>anti-PD-1/PD-L1</keyword>
  <keyword>anti-TIM-3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

